Boreal Genomics provides a platform that performs sensitive genomic analysis of cell-free DNA in plasma to detect and quantify mutations in tumor-derived circulating nucleic acids. The company offers its assay through both service and instrument offerings for research use only and expects the test will soon be certified for use in clinical studies. Boreal intends to use new financing to expand commercial operations in the translational research market, enhance laboratory capabilities and launch clinical applications for non-invasive genomic profiling and cancer monitoring. The company is expanding Bay Area facilities, including laboratory and commercial operations at a new location in Mountain View, California, and maintains a research and development site in Vancouver, British Columbia. Boreal is led by CEO Nitin Sood.

Total raised

$18M

Funding rounds

1

Latest round

Series C

Latest activity

Oct 2013